This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Since their discovery in 1949, cyanoacrylates have evoked great interest as being a possible ideal "tissue glue." Several different forms of these compounds have been developed in order to eliminate tissue toxicity. The first compound clinically tested was methyl-2-cyanoacrylate (Eastman 910 monomer). By 1970, the histotoxicity of this derivative became obvious, and it was considered unsafe for clinical trials. The same was found for isobutyl2-cyanoacrylate (Bucrylate). Attention was then turned toward a longer-chain monomer, butyl-2-cyanoacrylate (Histoacryl, Trihawk International, Montreal). Experimentation revealed Histoacryl to have a markedly reduced histotoxic effect on the tissues when compared with the smaller-chain monomers, methyl and isobutyl. Histoacryl has enjoyed widespread applications with uses including splenorenal anastomosis, temporary punctal occlusion of the lacrimal system, closure of upper eyelid blepharoplasties, and as an adhesive for onlay cartilaginous grafts.
This report describes the results of a six-month clinical trial conducted at the Lasky Clinic, Beverly Hills, Calif,
KAMER FM. Histoacryl. Arch Otolaryngol Head Neck Surg. 1988;114(10):1102–1103. doi:10.1001/archotol.1988.01860220036019
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: